Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4180101 | 0.88 | GPBAR1 (0.73) | LMNAGPBAR1KMT2ATSHRMCOLN3 | |
| SCHEMBL4184459 | 0.83 | GPBAR1 (0.74) | LMNAGPBAR1KMT2ATSHRMCOLN3 | |
| SCHEMBL14538033 | 0.83 | ALDH1A1 (0.71) | KMT2ATSHRALDH1A1PKMMAPT | |
| SCHEMBL16480610 | 0.83 | ALDH1A1 (0.73) | LMNAGPBAR1TSHRPOLBALDH1A1 | |
| SCHEMBL27334375 | 0.82 | KMT2A (0.58) | LMNAGPBAR1KMT2ATSHRMCOLN3 | |
| SCHEMBL8937378 | 0.81 | KMT2A (0.56) | GPBAR1KMT2ATSHRMCOLN3ALDH1A1 | |
| SCHEMBL24042726 | 0.81 | LMNA (0.61) | LMNAGPBAR1TSHRMCOLN3HTT | |
| SCHEMBL24322515 | 0.78 | ALDH1A1 (0.72) | LMNAKMT2ATSHRMCOLN3ALDH1A1 | |
| SCHEMBL1352340 | 0.77 | PKM (0.77) | LMNAKMT2ATSHRHTTALDH1A1 | |
| SCHEMBL4184681 | 0.77 | GPBAR1 (0.90) | LMNAGPBAR1TSHRMCOLN3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546397-B2 | DNA methylation inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120157465-A1 | DNA METHYLATION INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157465-A1 | DNA METHYLATION INHIBITORS | MECP2, DNMT1, DNMT3B | LMNA 614/4885GPBAR1 3135/4885KMT2A 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.